![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 10, 2023
These three trials are open and enrolling adults with multiple myeloma or at high risk of developing the disease
December 22, 2021
Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
August 17, 2021
This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
February 25, 2021
The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
December 14, 2020
The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
December 14, 2020
Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction
June 10, 2020
Strong EA research presence at ASCO 2020; the horrific killing of George Floyd; health equity and diversity in the field of oncology; the need for EA to participate in changing a specifically anti-racist culture and increase diversity and inclusion